title: Retreatment with peginterferon and ribavirin in chronic hepatitis C.
abstract: The development of boceprevir and telaprevir was a major step forward in the treatment of chronic hepatitis C. In addition, the treatment of these infections has been recently revolutionized by the approval of sofosbuvir and simeprevir. However, there are several challenges associated with the application of novel drugs, such as new and more frequent adverse events, new drug interactions, and excessively high treatment costs. An additional concern is viral resistance. These considerations highlight the fact that direct-acting antiviral agents are not a panacea and may not be the best option for all patients who are in need of therapy. This retrospective study revealed that the sustained virologic response was not significantly reduced following peginterferon and ribavirin retreatment compared with the new therapy. We suggest that patients who experience relapse shortly after completing treatment with peginterferon and ribavirin have a reasonable chance of achieving a sustained virologic response when retreated with these drugs alone.
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Yong Min
authors: YM
authors: Jo
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Sung Wook
authors: SW
authors: Lee
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Sang Young
authors: SY
authors: Han
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Yang Hyun
authors: YH
authors: Baek
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Soo Young
authors: SY
authors: Kim
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Woo Jae
authors: WJ
authors: Kim
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Ji Hye
authors: JH
authors: Ahn
authors: Yong Min Jo, Sung Wook Lee, Sang Young Han, Yang Hyun Baek, Soo Young Kim, Woo Jae Kim, Ji Hye Ahn, Ji Young Lee, Department of Internal Medicine, Dong-A University School of Medicine, Busan 602-715, South Korea.
authors: Ji Young
authors: JY
authors: Lee
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D019233:Retreatment; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a
keywords: Chronic hepatitis C; Direct-acting antiviral agents; Peginterferon; Retreatment; Ribavirin